Clinical Trial Update: Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients [Phase 3]

View source ↗

Summary

A Phase 3 multinational trial comparing isatuximab, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Kyprolis (carfilzomib)
• SARCLISA (isatuximab)

Snippet

Sponsor: Sanofi | Conditions: Plasma Cell Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2023-02-13